Abstract
The aim of this study was to evaluate the effect of single intravitreal ranibizumab injection in eyes with acute non-arteritic anterior ischemic optic neuropathy (NAION). The study includes a retrospective analysis of six eyes of six patients diagnosed with NAION. Mean time between visual loss and the intravitreal injection was 7.8 days (range 2– 15 days). The mean age of patients was 58.2 years (range 45– 63 years). Mean visual acuity gain was two Snellen's lines at the six-month follow-up. The mean optic nerve head peri-papillary thickness measured with spectral domain optical coherence tomography after one month decreased by an average of 230 microns. No complication related to the injection was observed during six months' follow-up. Our case series, the fi rst of its type from the Indian subcontinent, shows that patients with acute NAION may benefi t from intravitreal ranibizumab injection.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
